文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

急诊疑似感染患者抗生素给药时机与进展为脓毒性休克的关系

Antibiotic Timing and Progression to Septic Shock Among Patients in the ED With Suspected Infection.
PubMed 文献 · Chest · 2021-06-26
一句话结论急诊疑似感染(无休克)患者每延迟1小时使用抗生素,进展为脓毒性休克风险增加4.0%(校正病情严重度后,至24小时)。

该回顾性队列研究纳入2007年3月至2020年3月急诊疑似感染且分诊后24小时内使用首剂抗生素的成人患者,排除就诊时即有休克者,共74114例,其中5510例(7.4%)进展为脓毒性休克。多因素logistic模型显示,首剂抗生素给药时间(小时)与进展为脓毒性休克相关(OR 1.03,95%CI 1.02-1.04;P<.001),与院内死亡无显著相关(OR 1.02,95%CI 0.99-1.04;P=.121)。校正病情严重度后,分诊后每延迟1小时(至24小时)抗生素给药,进展为脓毒性休克风险增加4.0%。qSOFA阳性患者抗生素给药更早(0.82小时 vs 1.2小时;P<.05),但进展至脓毒性休克的中位时间更短(11.2小时 vs 26小时;P<.05)。

要点

  • 急诊疑似感染无休克患者,校正病情严重度后,分诊后每延迟1小时使用抗生素(至24小时),进展为脓毒性休克风险增加4.0%。
  • 多因素模型中,首剂抗生素给药时间每延迟1小时,进展为脓毒性休克OR 1.03(95%CI 1.02-1.04;P<.001)。
  • 首剂抗生素给药时间与院内死亡无显著相关(OR 1.02,95%CI 0.99-1.04;P=.121)。
  • qSOFA阳性患者抗生素给药更早(0.82小时 vs 1.2小时;P<.05),但进展至脓毒性休克中位时间更短(11.2小时 vs 26小时;P<.05)。
  • 进展为脓毒性休克的5510例(7.4%)中,88%在分诊后5小时内接受了抗生素。

适用人群与场景

  • 2007年3月至2020年3月急诊就诊的成人疑似感染患者,且分诊后24小时内使用首剂抗生素。
  • 排除就诊时即存在休克的患者。

研究设计与关键结果

  • 回顾性队列研究,纳入74114例急诊疑似感染患者,5510例(7.4%)进展为脓毒性休克。
  • 进展为脓毒性休克的患者中,88%在分诊后5小时内接受了抗生素。
  • 多因素logistic模型:首剂抗生素给药时间(小时)与进展为脓毒性休克OR 1.03(95%CI 1.02-1.04;P<.001);与院内死亡OR 1.02(95%CI 0.99-1.04;P=.121)。
  • 校正病情严重度后,分诊后每延迟1小时(至24小时)使用抗生素,进展为脓毒性休克风险增加4.0%。
  • qSOFA阳性患者抗生素给药时间早于SIRS阳性患者(0.82小时 vs 1.2小时;P<.05)。
  • qSOFA阳性患者进展至脓毒性休克的中位时间短于SIRS阳性患者(11.2小时 vs 26小时;P<.05)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,疑似感染患者延迟首剂抗生素与进展为脓毒性休克可能性快速增加相关。
  • 作者认为,qSOFA评分预测脓毒性休克的特异性高于SIRS评分,但与更差结局相关,即使患者接受了早期抗生素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Recent medical society opinions have questioned the use of early antimicrobials in patients with sepsis, but without septic shock.

RESEARCH QUESTION: Is time from ED presentation to administration of antibiotics associated with progression to septic shock among patients with suspected infection?

STUDY DESIGN AND METHODS: This was a retrospective cohort study from March 2007 through March 2020. All adults with suspected infection and first antimicrobial administered within 24 h of triage were included. Patients with shock on presentation were excluded. We performed univariate and multivariate logistic regression analyses predicting progression to septic shock.

RESULTS: Seventy-four thousand one hundred fourteen patient encounters were included in the study. Five thousand five hundred ten patients (7.4%) progressed to septic shock. Of the patients who progressed to septic shock, 88% had received antimicrobials within the first 5 h from triage. In the multivariate logistic model, time (in hours) to first antimicrobial administration showed an OR of 1.03 (95% CI, 1.02-1.04; P < .001) for progression to septic shock and 1.02 (95% CI, 0.99-1.04; P = .121) for in-hospital mortality. When adjusted for severity of illness, each hour delayed until initial antimicrobial administration was associated with a 4.0% increase in progression to septic shock for every 1 h up to 24 h from triage. Patients with positive quick Sequential Organ Failure Assessment (qSOFA) results were given antibiotics at an earlier time point than patients with positive systemic inflammatory response syndrome (SIRS) score (0.82 h vs 1.2 h; P < .05). However, median time to septic shock was significantly shorter (P < .05) for patients with positive qSOFA results at triage (11.2 h) compared with patients with positive SIRS score at triage (26 h).

INTERPRETATION: Delays in first antimicrobial administration in patients with suspected infection are associated with rapid increases in likelihood of progression to septic shock. Additionally, qSOFA score has higher specificity than SIRS score for predicting septic shock, but is associated with a worse outcome, even when patients receive early antibiotics.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Bisarya R, Song X, Salle J, et al. Antibiotic Timing and Progression to Septic Shock Among Patients in the ED With Suspected Infection. Chest. 2021. PMID: 34186038. doi:10.1016/j.chest.2021.06.029

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。